Anti-NANS (aa 54-341) polyclonal antibody

A new genus and species of small characid is described in this paper. The new genus, Nans gen. n., is diagnosed by the combination of: ii,7-8 dorsal-fin rays, 10-15 branched anal-fin rays, 5 teeth in the inner premaxillary row, rotation of the pelvic bone about 90degrees, rotation of the pelvic fin muscles, pelvic fin curved and forming a complete tube in mature males, incomplete foramen for exit of the olfactory nerve in the lateral ethmoid. Other characters which help in the identification of Nans are the large subcircular foramen in the dorsal vomerine lamella which articulates with the mesethmoid, the absence of an extrascapular sensory canal in the postemporal, and a laterosensory canal in the anguloarticular. The type species, Nans inde-fessus sp. n. was collected in the rio Anta Muerta and arroyo Colorado, tributaries of the rio Blanco, and in the rio Pescado, upper rio Bermejo basin, Salta, Argentina.

BackgroundGenome-wide and clinical studies have linked the 677C -> T polymorphism in the gene encoding methylenetetrahydrofolate reductase (MTHFR) with hypertension, whilst limited evidence shows that intervention with riboflavin (i.e. the MTHFR co-factor) can lower blood pressure (BP) in hypertensive patients with the variant MTHFR 677TT genotype. We investigated the impact of this common polymorphism on BP throughout adulthood and hypothesised that riboflavin status would modulate the genetic risk of hypertension.MethodsObservational data on 6076 adults of 18-102years were drawn from the Joint Irish Nutrigenomics Organisation project, comprising the Trinity-Ulster Department of Agriculture (TUDA; volunteer sample) and the National Adult Nutrition Survey (NANS; population-based sample) cohorts. Participants were recruited from the Republic of Ireland and Northern Ireland (UK) in 2008-2012 using standardised methods.ResultsThe variant MTHFR 677TT genotype was identified in 12% of adults. From 18 to 70years, this genotype was associated with an increased risk of hypertension (i.e. systolic BP >= 140 and/or a diastolic BP >= 90mmHg): odds ratio (OR) 1.42, 95% confidence interval (CI) 1.07 to 1.90; P=0.016, after adjustment for antihypertensive drug use and other significant factors, namely, age, male sex, BMI, alcohol and total cholesterol. Low or deficient biomarker status of riboflavin (observed in 30.2% and 30.0% of participants, respectively) exacerbated the genetic risk of hypertension, with a 3-fold increased risk for the TT genotype in combination with deficient riboflavin status (OR 3.00, 95% CI, 1.34-6.68; P=0.007) relative to the CC genotype combined with normal riboflavin status. Up to 65years, we observed poorer BP control rates on antihypertensive treatment in participants with the TT genotype (30%) compared to those without this variant, CT (37%) and CC (45%) genotypes (P<0.027).ConclusionsThe MTHFR 677TT genotype is associated with higher BP independently of homocysteine and predisposes adults to an increased risk of hypertension and poorer BP control with antihypertensive treatment, whilst better riboflavin status is associated with a reduced genetic risk. Riboflavin intervention may thus offer a personalised approach to prevent the onset of hypertension in adults with the TT genotype; however, this requires confirmation in a randomised trial in non-hypertensive adults.